Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 5 for:    Localized Scleroderma | Philadelphia, Pennsylvania, U.S.
Previous Study | Return to List | Next Study

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03740724
Recruitment Status : Recruiting
First Posted : November 14, 2018
Last Update Posted : January 28, 2021
Sponsor:
Information provided by (Responsible Party):
Castle Creek Biosciences, LLC.

Brief Summary:
A two-component therapeutic consisting of FCX-013 and veledimex for the treatment of localized scleroderma (or morphea). The first component, FCX-013, is autologous human fibroblasts genetically-modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), a protein responsible for breaking down collagen. FCX-013 is designed to be injected under the skin at the location of the fibrotic lesions where the genetically-modified fibroblast cells will produce MMP-1 to break down excess collagen accumulation. With the FCX-013 therapy, the patient will take an oral compound (Veledimex) to induce MMP-1 protein expression from the injected cells. Once the fibrosis is resolved, the patient will stop taking the oral compound which will stop further MMP-1 production from the injected cells. FCX-013 plus veledimex is being developed in anticipation of improving skin function in patients by resolving fibrotic lesions and normalizing dermal collagen production

Condition or disease Intervention/treatment Phase
Morphea Scleroderma, Localized Scleroderma Genetic: FCX-013 Drug: veledimex Phase 1 Phase 2

Detailed Description:
Castle Creek is developing a two-component therapeutic product for the treatment of moderate to severe localized scleroderma (morphea). The first component is FCX-013, an autologous genetically modified human dermal fibroblast (GM-HDFs) cell product that is genetically modified with a lentiviral vector (LV) to express human matrix metalloproteinase 1 (MMP1). MMP1 is also known as interstitial collagenase or fibroblast collagenase and is an enzyme that under normal physiological conditions breaks down the extracellular matrix. Specifically, MMP1 breaks down interstitial collagens, types I, II and III. In addition, the FCX-013 cells are also transduced with genetic constructs that encode the RheoSwitch Therapeutic System® (RTS®) an inducible promotor system that in the presence of a small molecule activator ligand controls expression of the MMP1 gene. The RTS® is activated to express MMP1 by the oral administration of the small molecule component. The purpose of this open-label single arm Phase 1/2 study is to investigate the safety and effectiveness of FCX-013 plus veledimex.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
Actual Study Start Date : December 18, 2019
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : January 2036


Arm Intervention/treatment
Experimental: FCX-013 + veledimex
Following the injection of FCX-013, subjects will initiate a 14-day course of veledimex to be taken orally daily
Genetic: FCX-013
FCX-013 is a genetically modified cell product obtained from the subject's own skin cells (autologous fibroblasts). The cells are expanded and genetically modified to express metalloproteinase-1 (MMP-1) under the control of a RheoSwitch (RTS®) system. FCX-013 cell suspension is injected intradermally.
Other Name: Genetically-Modified Autologous Human Dermal Fibroblasts

Drug: veledimex
Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration
Other Name: a small-molecule activator ligand for the RheoSwitch (RTS®) system




Primary Outcome Measures :
  1. Evaluate the safety of FCX-013 plus veledimex [ Time Frame: Study initiation through study completion ]
    Safety evaluations include assessment of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs); change in clinical laboratory values; change in vital signs; change in electrocardiograms (ECGs); and incidence of replication-competent lentivirus (RCL) antibodies.


Secondary Outcome Measures :
  1. Evaluate the antifibrotic effects of FCX-013 plus veledimex [ Time Frame: Week 4 ]
    Evaluate the antifibrotic effects of FCX-013 plus veledimex



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is an adult, ≥ 18 years of age with moderate to severe localized scleroderma/morphea with sclerotic lesions which have been unresponsive to standard of care therapy.
  • Subject has stable control of localized disease (clinically inactive) over the 3 months prior to Screening and through Baseline
  • Subject has not participated in previous clinical research study in the 3 months prior to Screening and through Baseline
  • Subject has provided informed written consent
  • Female subjects of childbearing potential and male subjects engaging in sexual activity that could lead to pregnancy agree to use adequate birth control regimen
  • Subject is able to understand the study, cooperate with the study procedures and willing to return to the clinic for the required follow-up visits

Exclusion Criteria:

  • Subject has a clinically significant skin disorder other than localized scleroderma/morphea in the anatomical area of interest
  • Subject has localized scleroderma/morphea only located on the face or over a joint, or lesions that can be successfully managed with topical medications or phototherapy
  • Subject has symptoms consistent with systemic scleroderma that have not been stable, or that require treatment that has not been stable for 3 months prior to Screening and through Baseline
  • Subject has been treated with UVA1 phototherapy within 2 months prior to Baseline
  • Subject requires treatment with a non-stable regimen of systemic immunosuppressive therapy, for any medical condition, or plans to initiate such treatment during the study period
  • Subject requires treatment with a non-stable regimen of physical therapy, for localized scleroderma/morphea, or plans to initiate such treatment during the study period.
  • Subject has any medical instability limiting ability to travel to the investigative center.
  • Subject has clinical signs of infection at (or in close proximity to) the target lesion.
  • Subject has a history of, or current, malignancy at/near site of injection (except basal cell carcinoma or squamous cell carcinoma that have been treated)
  • Subject has a history of, or current, clinically significant liver abnormalities.
  • Subject has a history of, or current, clinically significant cardiac abnormalities, or a significant abnormality on ECG
  • Subject has clinically significant laboratory abnormalities
  • Subject has active infection with human immunodeficiency virus (HIV), or hepatitis B/C
  • Subject has an active drug or alcohol addiction
  • Subject has any known allergy to any of the constituents of the product
  • Subject has received an interventional chemical or biological investigational study product for the specific treatment of localized scleroderma in the 3 months prior to Screening and through Baseline
  • Subject is pregnant or nursing or plans to become pregnant or nurse during the study period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03740724


Contacts
Layout table for location contacts
Contact: Hirak Routh, MD 215-563-7330 hirakbrouth@gmail.com
Contact: Jennifer Parish, MD 215-563-7330

Locations
Layout table for location information
United States, Pennsylvania
Paddington Testing Co., Inc. Recruiting
Philadelphia, Pennsylvania, United States, 19103
Contact: Hirak Routh, MD    215-563-7330    hirakbrouth@gmail.com   
Sponsors and Collaborators
Castle Creek Biosciences, LLC.
Layout table for additonal information
Responsible Party: Castle Creek Biosciences, LLC.
ClinicalTrials.gov Identifier: NCT03740724    
Other Study ID Numbers: FI-SC-001
First Posted: November 14, 2018    Key Record Dates
Last Update Posted: January 28, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Castle Creek Biosciences, LLC.:
Morphea
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Scleroderma, Localized
Connective Tissue Diseases
Skin Diseases